|
**Overview**: Chromosome Analysis Cord Blood Panel**Introduction**: The Chromosome Analysis Cord Blood Panel is a diagnostic tool designed to screen for neonatal chromosomal disorders using cord blood samples. In India, newborn screening for chromosomal anomalies (e.g., trisomy 21, sex chromosome disorders) is limited but critical in high-risk deliveries (preterm, IUGR, dysmorphism). Cord blood karyotyping allows immediate postnatal evaluation. High morbidity from underdiagnosis in rural deliveries, limited neonatal genetics access, delayed diagnosis leading to missed interventions. Per cytogenetics practices aligned with ICMR and Indian Academy of Pediatrics guidelines, the test employs karyotyping on cord blood lymphocytes over 1-2 days with high accuracy, valuable for rapid neonatal assessment. This diagnostic falls under neonatal screening and targets newborns with dysmorphism or high-risk features, addressing accurate detection to guide management and counseling. With elevated morbidity due to under-screening, the test supports public health efforts by enabling precise identification and reducing disability. Its cord blood-based approach ensures reliable fetal/neonatal cell analysis.**Other Names**: Cord Karyo Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.**Historical Milestone**: Cord blood karyotyping standard; in India, used in high-risk neonatal units.**Purpose**: The test performs 2 parameters including neonatal karyotype to guide detection of chromosomal abnormalities, identify anomalies, inform management.**Test Parameters**: 1. Neonatal Karyotype, 2. Chromosomal Abnormalities.**Pretest Condition**: No fasting required; newborns should have dysmorphism, IUGR, or high-risk delivery.**Specimen**: 3 mL cord blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate culture is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for karyotyping).**Medical History**: Parents should provide details on delivery complications, newborn dysmorphism, family genetic history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed chromosomal disorders including developmental issues, benefits of early detection, and minimal discomfort from cord blood collection.**Procedural Considerations**: The test involves sample processing using karyotyping (G-banding) by trained personnel to ensure sterile technique, culture lymphocytes, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell growth can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal neonatal karyotype indicates chromosomal disorder, necessitating specialist input. Normal may require follow-up if features suggestive.**Specialist Consultation**: Neonatologists or geneticists should be consulted for management.**Additional Supporting Tests**: CMA or FISH for confirmation.**Test Limitations**: Detects only gross abnormalities; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Neonatal Genetics Studies India 2023. |
